MBody AI Ltd. (MBAI) vs Exagen Inc. (XGN)

MBody AI Ltd. and Exagen Inc. are both Diagnostics & Research companies. Exagen Inc. is the larger, with a market value of $233.3M against $69.0M — 3.4× the size. MBody AI Ltd. has the higher net margin (0.00% vs −26.6%) and the higher return on invested capital (0.00% vs −68.3%). Across the 14 metrics below, MBody AI Ltd. leads on 10 and Exagen Inc. on 4.

Valuation

Metric MBAI XGN Diagnostics & Research median
P/E n/m n/m 33.95
P/S n/m 2.96 4.87
P/B 1.02 17.25 3.12
Price to free cash flow n/m n/m 34.02
EV/EBITDA n/m n/m 25.20
EV/Sales n/m 2.96 5.66
Earnings yield (457.38%) (9.29%) (1.75%)
Free cash flow yield (338.71%) (3.60%) (0.13%)

Profitability

Metric MBAI XGN Diagnostics & Research median
Gross margin 0.00% 58.64% 50.89%
Operating margin 0.00% (18.58%) (8.57%)
Net margin 0.00% (26.61%) (6.37%)
Free cash flow margin 0.00% (10.66%) 0.00%
Return on equity 0.00% (113.82%) (2.92%)
Return on assets 0.00% (34.19%) (6.71%)
Return on invested capital 0.00% (68.33%) 0.00%

Growth

Metric MBAI XGN Diagnostics & Research median
Revenue growth (TTM) — 20.83% 7.69%
EPS growth (last fiscal year) 115.35% (12.05%) —
Revenue growth, 5-year CAGR — 9.66% 7.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MBAI XGN Diagnostics & Research median
Debt to equity 0.00 2.00 0.11
Current ratio 0.71 3.18 2.02
Net debt to EBITDA 0.09 0.68 0.78

Dividend

Metric MBAI XGN Diagnostics & Research median
Dividend yield — — 0.70%
Payout ratio 0.00 0.00 0.00

Size

Metric MBAI XGN Diagnostics & Research median
Market cap 68.97m 233.29m 2.56b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack